ArticleCancer immunology, immunotherapy : CII2026
Photothermal therapy synergizes with CD47 blockade by inducing calreticulin exposure and remodeling the tumor extracellular matrix in oral squamous cell carcinoma.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies.Smart molecules : open access · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) overexpresses CD47, enabling immune evasion via a "don't eat me" signal to macrophages. Although CD47 blockade shows promise, its efficacy is limited due to a lack of "eat me" signal and contact between macrophages and tumor cells.
objectivesThis study aimed to evaluate the synergistic anti-tumor effect of combining photothermal therapy (PTT) with CD47 blockade in OSCC and elucidate the underlying mechanisms.
methodsIn vitro phagocytosis was assessed by flow cytometry. In vivo anti-tumor efficacy was measured by tumor growth inhibition. Mechanistic studies included detection of immunogenic cell death (ICD) markers (ATP, HMGB1, calreticulin (CRT)), confocal microscopy for CRT-macrophage co-localization, analysis of ECM component expression, and immunofluorescence for macrophage infiltration.
resultsThe combination of PTT and CD47 blockade significantly enhanced macrophage phagocytosis in vitro and strongly inhibited tumor growth in vivo. PTT induced ICD, as evidenced by the release of ATP and HMGB1, and the exposure of CRT on the cell membrane. Confocal microscopy confirmed co-localization of CRT-expressing tumor cells with macrophages. Furthermore, PTT down-regulated ECM components at transcriptional and protein levels, which correlated with increased macrophage infiltration into tumors.
conclusionsPTT synergizes with CD47 blockade primarily by inducing CRT-dependent pro-phagocytic signaling to provide the "eat me" signal. In parallel, PTT downregulates ECM components, enabling the essential "come near me" process that facilitates macrophage infiltration into tumors. This dual approach significantly improves the macrophage based anti-tumor efficacy of CD47 blockade.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.